2007: RA New Treatments Clinical Trials I

RA New Treatments Clinical Trials I

695

Ocrelizumab, a Novel Humanized Anti-CD20 Antibody: Week 72 Results from a Phase I/II Clinical Trial in Patients with Rheumatoid Arthritis

696

Liquid Formulation Certolizumab Pegol with Methotrexate Decreases Progression of Structural Joint Damage in Rheumatoid Arthritis Patients: The RAPID 2 Study

697

Clinical and Radiological Efficacy of Four Different Treatment Strategies in Patients with Recent Onset Rheumatoid Arthritis: 4-year Follow-up of the Best Study

698

Denosumab Inhibits RANKL, Reducing Progression of the Total Sharp Score and Bone Erosions in Patients With Rheumatoid Arthritis: 12-month X-Ray Results

699

Long-Term Efficacy and Safety of Abatacept through 3 Years of Treatment in Rheumatoid Arthritis Patients in the AIM and ATTAIN Trials

700

The Anti-TNF Certolizumab Pegol in Combination with Methotrexate is Significantly More Effective than Methotrexate Alone in the Treatment of Patients with Active Rheumatoid Arthritis: 1-Year Results from the RAPID 1 Study

See more of: ACR Abstract Submission ACR Concurrent Abstract Session

<< Previous Session Level | Next Session Level >>